JPS5538325A
(en)
*
|
1978-09-11 |
1980-03-17 |
Sankyo Co Ltd |
4-anilinoquinazoline derivative and its preparation
|
JPS57144266A
(en)
*
|
1981-03-04 |
1982-09-06 |
Sankyo Co Ltd |
4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component
|
JP2676082B2
(ja)
*
|
1987-12-25 |
1997-11-12 |
住友化学工業株式会社 |
ゴキブリ防除用マイクロカプセル剤
|
US5710158A
(en)
*
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5721237A
(en)
*
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
US5714493A
(en)
*
|
1991-05-10 |
1998-02-03 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5480883A
(en)
*
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
EP0584222B1
(de)
*
|
1991-05-10 |
1997-10-08 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
|
USRE37650E1
(en)
|
1991-05-10 |
2002-04-09 |
Aventis Pharmacetical Products, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US6645969B1
(en)
*
|
1991-05-10 |
2003-11-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5733561A
(en)
*
|
1991-06-12 |
1998-03-31 |
Mitsui Toatsu Chemicals, Incorporated |
Insecticide composition and production process thereof
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5234936A
(en)
*
|
1991-10-24 |
1993-08-10 |
American Home Products Corporation |
Pyrimidocycloalkanes as a ii antagonists
|
AU661533B2
(en)
*
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2049659B1
(es)
*
|
1992-10-08 |
1994-10-16 |
Ici Plc |
Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
|
GB9314893D0
(en)
*
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
AU739382B2
(en)
*
|
1993-12-10 |
2001-10-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US6232465B1
(en)
|
1994-09-02 |
2001-05-15 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US6214987B1
(en)
|
1994-09-02 |
2001-04-10 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
|
TW321649B
(de)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
AU5343096A
(en)
*
|
1995-04-27 |
1996-11-18 |
Zeneca Limited |
Quinazoline derivatives
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
ES2194181T3
(es)
*
|
1996-02-13 |
2003-11-16 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de vegf.
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DK0885198T3
(da)
*
|
1996-03-05 |
2002-03-25 |
Astrazeneca Ab |
4-Anilinoquinazolinderivater
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
US5939421A
(en)
*
|
1997-07-01 |
1999-08-17 |
Signal Pharmaceuticals, Inc. |
Quinazoline analogs and related compounds and methods for treating inflammatory conditions
|
US6706721B1
(en)
*
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
JP2002516823A
(ja)
|
1998-05-28 |
2002-06-11 |
パーカー ヒューズ インスティテュート |
脳腫瘍の治療のためのキナゾリン
|
US6800649B1
(en)
|
1998-06-30 |
2004-10-05 |
Parker Hughes Institute |
Method for inhibiting c-jun expression using JAK-3 inhibitors
|
WO2000010981A1
(en)
|
1998-08-21 |
2000-03-02 |
Parker Hughes Institute |
Quinazoline derivatives
|
US6080747A
(en)
*
|
1999-03-05 |
2000-06-27 |
Hughes Institute |
JAK-3 inhibitors for treating allergic disorders
|
US6258820B1
(en)
|
1999-03-19 |
2001-07-10 |
Parker Hughes Institute |
Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
|
KR100881105B1
(ko)
|
1999-11-05 |
2009-02-02 |
아스트라제네카 아베 |
Vegf 억제제로서의 퀴나졸린 유도체
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
DE60121931T2
(de)
|
2000-04-07 |
2007-03-01 |
Astrazeneca Ab |
Chinazolinverbindungen
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
WO2003009815A2
(en)
|
2001-07-25 |
2003-02-06 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
DE60231230D1
(de)
*
|
2001-11-03 |
2009-04-02 |
Astrazeneca Ab |
Quinazolin derivate als antitumor-mittel
|
TWI324597B
(en)
*
|
2002-03-28 |
2010-05-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6924285B2
(en)
*
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309850D0
(en)
*
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
CA2531327A1
(en)
*
|
2003-07-03 |
2005-01-13 |
Myriad Genetics, Inc. |
Compounds and therapeutical use thereof
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
GB0321648D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Astrazeneca Ab |
Quinazoline derivatives
|
MXPA06002963A
(es)
*
|
2003-09-16 |
2006-06-14 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de cinasa de tirosina.
|
EP1667992B1
(de)
|
2003-09-19 |
2007-01-24 |
Astrazeneca AB |
Chinazolinderivate
|
ES2281007T3
(es)
*
|
2003-09-19 |
2007-09-16 |
Astrazeneca Ab |
Derivados de quinazolina.
|
BRPI0414735A
(pt)
*
|
2003-09-25 |
2006-11-21 |
Astrazeneca Ab |
derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
|
CN1890223A
(zh)
*
|
2003-10-31 |
2007-01-03 |
神经能质公司 |
辣椒素受体促效剂
|
GB0326459D0
(en)
*
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
US20070232607A1
(en)
*
|
2004-06-04 |
2007-10-04 |
Bradbury Robert H |
Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
|
US20070244114A1
(en)
*
|
2004-07-06 |
2007-10-18 |
Myriad Genetics, Incorporated |
Compounds and therapeutical use thereof
|
US7947676B2
(en)
|
2004-12-14 |
2011-05-24 |
Astrazeneca Ab |
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
|
CA2592900A1
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
US8258145B2
(en)
*
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
WO2006090163A1
(en)
*
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
GB0504474D0
(en)
*
|
2005-03-04 |
2005-04-13 |
Astrazeneca Ab |
Chemical compounds
|
SI1889198T1
(sl)
|
2005-04-28 |
2015-02-27 |
Proteus Digital Health, Inc. |
Farma-informacijski sistem
|
GB0508717D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
WO2007034144A1
(en)
*
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
WO2007034143A1
(en)
*
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
Quinazoline derivatives as anticancer agents
|
CN101321739A
(zh)
*
|
2005-12-02 |
2008-12-10 |
阿斯利康(瑞典)有限公司 |
用作erbB酪氨酸激酶抑制剂的喹唑啉衍生物
|
JP2009517450A
(ja)
*
|
2005-12-02 |
2009-04-30 |
アストラゼネカ アクチボラグ |
チロシンキナーゼ阻害薬としての4−アニリノ置換キナゾリン誘導体
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
US9259426B2
(en)
*
|
2006-07-20 |
2016-02-16 |
Gilead Sciences, Inc. |
4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
US8246966B2
(en)
*
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
MX2009002893A
(es)
|
2006-09-18 |
2009-07-10 |
Raptor Pharmaceutical Inc |
Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
CA2669531A1
(en)
|
2006-11-22 |
2008-06-05 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
|
CA2677336A1
(en)
*
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
|
NZ586582A
(en)
|
2008-02-07 |
2012-07-27 |
Boehringer Ingelheim Int |
Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
|
ES2444128T3
(es)
|
2008-05-13 |
2014-02-24 |
Astrazeneca Ab |
Nueva SAL-554
|
JP5539351B2
(ja)
|
2008-08-08 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
|
ES2728225T3
(es)
|
2009-02-20 |
2019-10-23 |
2 Bbb Medicines B V |
Sistema de administración de fármacos a base de glutatión
|
AU2010245823B2
(en)
|
2009-05-06 |
2016-11-24 |
Laboratory Skin Care, Inc. |
Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
CN110372666B
(zh)
*
|
2018-04-13 |
2022-11-08 |
华东理工大学 |
喹唑啉类化合物作为egfr三突变抑制剂及其应用
|
CN113811528A
(zh)
|
2019-03-15 |
2021-12-17 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|